The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
S-1/docetaxel compared with the other standard S-1 based regimens as a first-line chemotherapy for patients with advanced gastric cancer.
Tetsuya Kusumoto
No relevant relationships to disclose
Koji Ando
No relevant relationships to disclose
Satoshi Ida
No relevant relationships to disclose
Yasue Kimura
No relevant relationships to disclose
Hiroshi Saeki
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Masaru Morita
No relevant relationships to disclose
Yoshihiko Maehara
No relevant relationships to disclose